{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T04:53:41Z","timestamp":1662440021319},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s11940-019-0561-6","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T07:29:55Z","timestamp":1554362995000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["OnabotulinumtoxinA in Migraine and Other Headaches: Review and Update"],"prefix":"10.1007","volume":"21","author":[{"given":"Marc E.","family":"Lenaerts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany H.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,4]]},"reference":[{"issue":"9","key":"561_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, (beta version). Cephalalgia. 2013;33(9):629\u2013808.","journal-title":"Cephalalgia"},{"issue":"7","key":"561_CR2","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","volume":"27","author":"HC Diener","year":"2007","unstructured":"Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27(7):814\u201323.","journal-title":"Cephalalgia"},{"issue":"8","key":"561_CR3","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1526-4610.2009.01508.x","volume":"49","author":"S Silberstein","year":"2009","unstructured":"Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009;49(8):1153\u201362.","journal-title":"Headache"},{"issue":"6","key":"561_CR4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425\u201334.","journal-title":"Lancet Neurol"},{"issue":"22","key":"561_CR5","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113\u201322.","journal-title":"N Engl J Med"},{"issue":"24","key":"561_CR6","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211\u201321.","journal-title":"Neurology."},{"issue":"suppl 2","key":"561_CR7","first-page":"241","volume":"13","author":"W Binder","year":"1998","unstructured":"Binder W, Brin MF, Blitzer A, Schenrock L, Diamond B. Botulinum toxin type A (BTX-A) for migraine: an open label assessment [abstract]. Mov Disord. 1998;13(suppl 2):241.","journal-title":"Mov Disord"},{"issue":"6","key":"561_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1046\/j.1526-4610.2000.00066.x","volume":"40","author":"S Silberstein","year":"2000","unstructured":"Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000;40(6):445\u201350.","journal-title":"Headache"},{"issue":"7","key":"561_CR9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"\u2022\u2022 Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793\u2013803. A pivotal study in FDA-approval of onabotulinumtoxinA in treatment of chronic migraine.","journal-title":"Cephalalgia"},{"issue":"7","key":"561_CR10","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"DW Dodick","year":"2010","unstructured":"\u2022\u2022 Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804\u201314. A pivotal study in FDA-approval of onabotulinumtoxinA in treatment of chronic migraine.","journal-title":"Cephalalgia"},{"key":"561_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1526-4610.2005.05066.x","volume":"45","author":"NT Mathew","year":"2005","unstructured":"Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45:293\u2013307.","journal-title":"Headache"},{"key":"561_CR12","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.4065\/80.9.1126","volume":"80","author":"SD Silberstein","year":"2005","unstructured":"Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005;80:1126\u201337.","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"561_CR13","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","volume":"50","author":"A Blumenfeld","year":"2010","unstructured":"Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50(9):1406\u201318.","journal-title":"Headache"},{"issue":"3","key":"561_CR14","doi-asserted-by":"publisher","first-page":"e1270","DOI":"10.1097\/GOX.0000000000001270","volume":"5","author":"JE Janis","year":"2017","unstructured":"Janis JE, Barker JC, Palettas M. Targeted peripheral nerve-directed onabotulinumtoxin A injection for effective long-term therapy for migraine headache. Plast Reconstr Surg Glob Open. 2017;5(3):e1270.","journal-title":"Plast Reconstr Surg Glob Open."},{"issue":"1","key":"561_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10194-017-0784-4","volume":"18","author":"M Matharu","year":"2017","unstructured":"Matharu M, Halker R, Pozo-Rosich P, DeGryse R, Manack Adams A, Aurora SK. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. J Headache Pain. 2017;18(1):78.","journal-title":"J Headache Pain"},{"issue":"1","key":"561_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s10194-018-0840-8","volume":"19","author":"AM Blumenfeld","year":"2018","unstructured":"Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13.","journal-title":"J Headache Pain"},{"issue":"10","key":"561_CR17","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s10072-017-3054-y","volume":"38","author":"A Santoro","year":"2017","unstructured":"Santoro A, Fontana A, Miscio AM, Zarrelli MM, Copetti M, Leone MA. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting. Neurol Sci. 2017;38(10):1779\u201389.","journal-title":"Neurol Sci"},{"key":"561_CR18","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3389\/fneur.2017.00586","volume":"8","author":"S Guerzoni","year":"2017","unstructured":"Guerzoni S, Pellesi L, Baraldi C, Cainazzo MM, Negro A, Martelletti P, et al. Long-term treatment benefits and prolonged efficacy of onabotulinumtoxinA in patients affected by chronic migraine and medication overuse headache over 3 years of therapy. Front Neurol. 2017;8:586.","journal-title":"Front Neurol"},{"issue":"15","key":"561_CR19","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1212\/WNL.0b013e318232ab65","volume":"77","author":"RB Lipton","year":"2011","unstructured":"Lipton RB, Varon SF, Grosberg B, McAllister PJ, Freitag F, Aurora SK, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology. 2011;77(15):1465\u201372.","journal-title":"Neurology"},{"issue":"10","key":"561_CR20","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/head.12456","volume":"54","author":"JF Rothrock","year":"2014","unstructured":"Rothrock JF, Bloudek LM, Houle TT, Andress-Rothrock D, Varon SF. Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine. Headache. 2014;54(10):1565\u201373.","journal-title":"Headache"},{"key":"561_CR21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40064-015-1636-9","volume":"4","author":"A Negro","year":"2015","unstructured":"Negro A, Curto M, Lionetto L, Crialesi D, Martelletti P. OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. Springerplus. 2015;4:286.","journal-title":"Springerplus"},{"issue":"9","key":"561_CR22","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/head.12657","volume":"55","author":"K Maasumi","year":"2015","unstructured":"Maasumi K, Thompson NR, Kriegler JS, Tepper SJ. Effect of OnabotulinumtoxinA injection on depression in chronic migraine. Headache. 2015;55(9):1218\u201324.","journal-title":"Headache"},{"issue":"4","key":"561_CR23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1177\/0333102416648328","volume":"37","author":"DF Bratbak","year":"2017","unstructured":"Bratbak DF, Nordgard S, Nordgard S, Linde M, Dodick D, Aschehoug I, et al. Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine. Cephalalgia. 2017;37(4):356\u201364.","journal-title":"Cephalalgia"},{"issue":"2","key":"561_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/ene.13523","volume":"25","author":"C Dom\u00ednguez","year":"2018","unstructured":"Dom\u00ednguez C, Pozo-Rosich P, Torres-Ferr\u00fas M, Hern\u00e1ndez-Beltr\u00e1n N, Jurado-Cobo C, Gonz\u00e1lez-Oria C, et al. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study. Eur J Neurol. 2018;25(2):411\u20136.","journal-title":"Eur J Neurol"},{"issue":"1","key":"561_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s10194-017-0744-z","volume":"18","author":"G Sandrini","year":"2017","unstructured":"Sandrini G, De Icco R, Tassorelli C, Smania N, Tamburin S. Botulinum neurotoxin type a for the treatment of pain: not just in migraine and trigeminal neuralgia. J Headache Pain. 2017;18(1):38.","journal-title":"J Headache Pain"},{"issue":"supplement 1","key":"561_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-004-1102-z","volume":"251","author":"S Mense","year":"2004","unstructured":"Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol. 2004;251(supplement 1):1\u20137.","journal-title":"J Neurol"},{"issue":"8","key":"561_CR27","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/jcmm.12562","volume":"19","author":"L Bittencourt da Silva","year":"2015","unstructured":"Bittencourt da Silva L, N\u00f8rgaard Poulsen J, Arendt-Nielsen L, Gazerani P. Botulinum neurotoxin type A modulates vesicular release of glutamate from satellite glial cells. J Cell Mol Med. 2015;19(8):1900\u20139.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"561_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.nbd.2012.07.010","volume":"48","author":"T Shimizu","year":"2012","unstructured":"Shimizu T, Shibata M, TorUmi H, et al. Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol Dis. 2012;48(3):367\u201378.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"561_CR29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/membranes4030525","volume":"4","author":"C Ferrandiz-Huertas","year":"2014","unstructured":"Ferrandiz-Huertas C, Mathivanan S, Wolf CJ, Devesa I, Ferrer-Montiel A. Trafficking of thermo TRP channels. Membranes. 2014;4(3):525\u201364.","journal-title":"Membranes"},{"issue":"1","key":"561_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/1073858414524633","volume":"21","author":"R Mazzocchio","year":"2015","unstructured":"Mazzocchio R, Caleo M. More than at the neuromuscular synapse: actions of botulinum neurotoxin a in the central nervous system. Neuroscientist. 2015;21(1):44\u201361.","journal-title":"Neuroscientist"},{"issue":"10","key":"561_CR31","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s00702-017-1764-1","volume":"124","author":"L Paracka","year":"2017","unstructured":"Paracka L, Kollewe K, Wegner F, Dressler D. Strategies to decrease injection site pain in botulinum toxin therapy. J Neural Transm. 2017;124(10):1213\u201312116.","journal-title":"J Neural Transm"},{"issue":"1\u20132","key":"561_CR32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pain.2004.01.016","volume":"109","author":"WJ Schulte-Mattler","year":"2004","unstructured":"Schulte-Mattler WJ, Krack P. BoNTTH Study Group. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain. 2004;109(1\u20132):110\u20134.","journal-title":"Pain"},{"issue":"7","key":"561_CR33","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1046\/j.1526-4610.2001.041007658.x","volume":"41","author":"WJ Schmitt","year":"2001","unstructured":"Schmitt WJ, Slowey E, Fravi N, Weber S, Burgunder JM. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache. 2001;41(7):658\u201364.","journal-title":"Headache"},{"issue":"1","key":"561_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s10194-018-0874-y","volume":"19","author":"C Lampl","year":"2018","unstructured":"Lampl C, Rudolph M, Br\u00e4utigam E. OnabotulinumtoxinA in the treatment of refractory chronic cluster headache. J Headache Pain. 2018;19(1):45.","journal-title":"J Headache Pain"},{"issue":"10","key":"561_CR35","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1111\/head.13398","volume":"58","author":"I Aschehoug","year":"2018","unstructured":"\u2022 Aschehoug I, Bratbak DF, Tronvik EA. Long-term outcome of patients with intractable chronic cluster headache treated with injection of onabotulinum toxin a toward the sphenopalatine ganglion - an observational study. Headache. 2018;58(10):1519\u201329. Original and promising approach for cluster headache treatment.","journal-title":"Headache"},{"key":"561_CR36","first-page":"7365148","volume":"2018","author":"J Lu","year":"2018","unstructured":"Lu J, Xu YY, Zhang QL, Luo WF. Efficacy and safety of botulinum toxin type A in treating patients of advanced age with idiopathic trigeminal neuralgia. Pain Res Manag. 2018;2018:7365148 eCollection.","journal-title":"Pain Res Manag"},{"key":"561_CR37","first-page":"831094","volume":"2013","author":"G Verma","year":"2013","unstructured":"Verma G. Role of botulinum toxin type-A (BTX-A) in the management of trigeminal neuralgia. Pain Res Treat. 2013;2013:831094.","journal-title":"Pain Res Treat."},{"issue":"10","key":"561_CR38","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/AJP.0b013e31827a72d2","volume":"29","author":"Z Apalla","year":"2013","unstructured":"Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin A in post-herpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain. 2013;29(10):857\u201364.","journal-title":"Clin J Pain"},{"issue":"11","key":"561_CR39","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/j.1526-4637.2011.01245.x","volume":"12","author":"B Jabbari","year":"2011","unstructured":"Jabbari B, Machado D. Treatment of refractory pain with botulinum toxins -an evidence-based review. Pain Med. 2011;12(11):1594\u2013606.","journal-title":"Pain Med"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-019-0561-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-019-0561-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-019-0561-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T23:21:19Z","timestamp":1585869679000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-019-0561-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["561"],"URL":"https:\/\/doi.org\/10.1007\/s11940-019-0561-6","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"4 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Marc Lenaerts is a member of Speakers Bureaus of Amgen, Allergan, and Teva Pharmaceuticals. Tiffany Green declares no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"21"}}